Clinical comprehensive evaluation of potassium-competitive acid blockers
OBJECTIVE To conduct a clinical comprehensive evaluation of potassium-competitive acid blockers (P-CAB) and provide reference for medical institutions to select new drugs,optimize drug catalogs,and use such drugs reasonably. METHODS clinical application guidelines,expert consensus,drug instructions,drug registration data (including phase Ⅲ clinical trials),meta-analysis/systematic review of databases such as PubMed and CNKI related to Vonoprazan fumarate tablets,Tegorasen tablets,and Keverprazan hydrochloride tablets already on the market in China were collected and organized. Based on the Quick Guidelines for Drug Evaluation and Selection in Chinese Medical Institutions (Second Edition),a comprehensive evaluation of the three P-CAB drugs was conducted from five dimensions:pharmaceutical characteristics,efficacy,safety,economy,and the other property. RESULTS The five dimensions of the three P-CAB were ranked from high to low as follows:Vonoprazan fumarate tablets (81.8 points),Tegorasen tablets (75.7 points),and Keverprazan hydrochloride tablets (75.6 points). Among them,Vonoprazan fumarate tablets scored the highest in 4 dimensions of pharmaceutical properties,efficacy,economy,and the other property;but the safety score was slightly low. CONCLUSIONS The three types of P-CAB are comprehensively strongly recommended and demonstrated good clinical efficacy. Vonoprazan fumarate tablets have more advantages in terms of pharmaceutical properties,efficacy,and economy.
万方数据
维普
